Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 876-883

  Vonderheide, Robert H ^a   Flaherty, Keith T ^a   Khalil, Magi ^a   Stumacher, Molly S ^a   Bajor, David L ^a   Hutnick, Natalie A ^a   Sullivan, Patricia ^a   Mahany, J Joseph ^a   Gallagher, Maryann ^a   Kramer, Amy ^a   Green, Stephanie J ^a   O'Dwyer, Peter J ^a   Running, Kelli L ^a   Huhn, Richard D ^a   Antonia, Scott J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 AGONIST MONOCLONAL ANTIBODY; CP 870 893; D DIMER; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD40 ANTIGEN; CP 870,893; CP-870,893; CYTOKINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BILE DUCT CARCINOMA; BONE PAIN; BREAST CANCER; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FEMALE; FLOW CYTOMETRY; HUMAN; HYPOXIA; IMMUNOMODULATION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MONOCYTE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RIGOR; SARCOMA; SEIZURE; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; THROMBOCYTE; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT OUTCOME; UPREGULATION; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; LIVER; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL; SECRETION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 33947506186     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.3311     Document Type: Article

References (30)

1. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 67:2-17, 2000
2. Eliopoulos AG, Young LS: The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4:360-367, 2004
3. Tong AW, Stone MJ: Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10:1-13, 2003
4. Banchereau J, Bazan F, Blanchard D, et al: The CD40 antigen and its ligand. Annu Rev Immunol 12:881-922, 1994
5. Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16:111-135, 1998
6. Armitage RJ, Fanslow WC, Strockbine L, et al: Molecular and biological characterization of a murine ligand for CD40. Nature 357:80-82, 1992
7. Bennett SR, Carbone FR, Karamalis F, et al: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480, 1998
8. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T- helper and a T-killer cell. Nature 393:474-478, 1998
9. Schoenberger SP, Toes RE, van der Voort EI, et al: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483, 1998
10. French RR, Chan HT, Tutt AL, et al: CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5:548-553, 1999
11. Diehl L, den Boer AT, Schoenberger SP, et al: CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5:774-779, 1999
12. Sotomayor EM, Borrello I, Tubb E, et al: Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5:780-787, 1999
13. van Mierlo GJ, den Boer AT, Medema JP, et al: CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A 99:5561-5566, 2002
14. Hess S, Engelmann H: A novel function of CD40: Induction of cell death in transformed cells. J Exp Med 183:159-167, 1996
15. Wingett DG, Vestal RE, Forcier K, et al: CD40 is functionally expressed on human breast carcinomas: Variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 50:27-36, 1998
16. Hirano A, Longo DL, Taub DD, et al: Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93:2999-3007, 1999
17. von Leoprechting A, van der Bruggen P, Pahl HL, et al: Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59:1287-1294, 1999
18. Eliopoulos AG, Davies C, Knox PG, et al: CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 20:5503-5515, 2000
19. Bedian V, Donovan C, Garder J, et al: In vitro characterization and pre-clinical pharmacokinetics of CP-870,893, a human anti-CD40 agonist antibody. J Clin Oncol 24:109s, 2006 (suppl; abstr 2539)
20. Gladue R, Cole S, Donovan C, et al: In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: Impact of tumor CD40 expression, dendritic cells, and chemotherapy. J Clin Oncol 24:103s, 2006 (suppl; abstr 2514)
21. Ribas A, Camacho LH, Lopez-Berestein G, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23:8968-8977, 2005
22. Afford SC, Randhawa S, Eliopoulos AG, et al: CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med 189:441-446, 1999
23. Karmann K, Hughes CC, Schechner J, et al: CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A 92:4342-4346, 1995
24. Dechanet J, Grosset C, Taupin JL, et al: CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 159:5640-5647, 1997
25. Zhou L, Stordeur P, de Lavareille A, et al: CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost 79:1025-1028, 1998
26. Miller DL, Yaron R, Yellin MJ: CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 63:373-379, 1998
27. Thienel U, Loike J, Yellin MJ: CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol 198:87-95, 1999
28. Vonderheide RH, Dutcher JP, Anderson JE, et al: Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19:3280-3287, 2001
29. Schultze JL, Michalak S, Seamon MJ, et al: CD40 activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100:2757-2765, 1997
30. Coughlin CM, Vance BA, Grupp SA, et al: RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: Implications for pediatric immunotherapy. Blood 103:2046-2054, 2004